# 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

> **NCT05633160** · PHASE1,PHASE2 · TERMINATED · sponsor: **Clarity Pharmaceuticals Ltd** · enrollment: 4 (actual)

## Conditions studied

- Prostatic Neoplasms
- Castration-Resistant

## Interventions

- **DRUG:** 64Cu-SAR-BBN
- **DRUG:** 67Cu-SAR-BBN

## Key facts

- **NCT ID:** NCT05633160
- **Lead sponsor:** Clarity Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-15
- **Primary completion:** 2025-04-23
- **Final completion:** 2025-04-23
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05633160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05633160, "64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05633160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*